Medicinova Stock EBITDA
| MNOV Stock | USD 2.00 0.05 2.56% |
MediciNova fundamentals help investors to digest information that contributes to MediciNova's financial success or failures. It also enables traders to predict the movement of MediciNova Stock. The fundamental analysis module provides a way to measure MediciNova's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to MediciNova stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | -9.9 M | -10.4 M |
MediciNova | EBITDA |
MediciNova Company EBITDA Analysis
MediciNova's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current MediciNova EBITDA | (9.88 M) |
Most of MediciNova's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, MediciNova is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
MediciNova EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for MediciNova is extremely important. It helps to project a fair market value of MediciNova Stock properly, considering its historical fundamentals such as EBITDA. Since MediciNova's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of MediciNova's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of MediciNova's interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
MediciNova Ebitda
According to the company disclosure, MediciNova reported earnings before interest,tax, depreciation and amortization of (9.88 Million). This is 101.13% lower than that of the Biotechnology sector and 109.86% lower than that of the Health Care industry. The ebitda for all United States stocks is 100.25% higher than that of the company.
MediciNova EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses MediciNova's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of MediciNova could also be used in its relative valuation, which is a method of valuing MediciNova by comparing valuation metrics of similar companies.MediciNova is currently under evaluation in ebitda category among its peers.
MediciNova Current Valuation Drivers
We derive many important indicators used in calculating different scores of MediciNova from analyzing MediciNova's financial statements. These drivers represent accounts that assess MediciNova's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of MediciNova's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 290.9M | 233.6M | 130.2M | 100.5M | 90.5M | 99.2M | |
| Enterprise Value | 227.5M | 173.8M | 58.9M | 82.2M | 74.0M | 82.8M |
MediciNova Institutional Holders
Institutional Holdings refers to the ownership stake in MediciNova that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of MediciNova's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing MediciNova's value.| Shares | Bank Of America Corp | 2024-06-30 | 118.7 K | Bank Of New York Mellon Corp | 2024-06-30 | 96.2 K | Barclays Plc | 2024-06-30 | 83.2 K | Charles Schwab Investment Management Inc | 2024-09-30 | 71.5 K | Dimensional Fund Advisors, Inc. | 2024-09-30 | 61.3 K | Schonfeld Strategic Advisors Llc | 2024-06-30 | 41.7 K | Millennium Management Llc | 2024-06-30 | 24.9 K | T. Rowe Price Associates, Inc. | 2024-06-30 | 20.7 K | Citadel Advisors Llc | 2024-06-30 | 18.2 K | Essex Woodlands Health Ventures | 2024-09-30 | 1.1 M | Blackrock Inc | 2024-06-30 | 694.9 K |
MediciNova Fundamentals
| Return On Equity | -0.13 | ||||
| Return On Asset | -0.0951 | ||||
| Operating Margin | (9.82) % | ||||
| Current Valuation | 53.94 M | ||||
| Shares Outstanding | 49.05 M | ||||
| Shares Owned By Insiders | 2.98 % | ||||
| Shares Owned By Institutions | 21.30 % | ||||
| Number Of Shares Shorted | 182.2 K | ||||
| Price To Earning | (24.69) X | ||||
| Price To Book | 1.71 X | ||||
| Price To Sales | 98.09 X | ||||
| Revenue | 1000 K | ||||
| Gross Profit | 4.04 M | ||||
| EBITDA | (9.88 M) | ||||
| Net Income | (8.57 M) | ||||
| Cash And Equivalents | 65.23 M | ||||
| Cash Per Share | 1.33 X | ||||
| Total Debt | 215.93 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 17.17 X | ||||
| Book Value Per Share | 1.27 X | ||||
| Cash Flow From Operations | (7.43 M) | ||||
| Short Ratio | 11.20 X | ||||
| Earnings Per Share | (0.16) X | ||||
| Price To Earnings To Growth | (0.94) X | ||||
| Target Price | 8.0 | ||||
| Number Of Employees | 13 | ||||
| Beta | 0.77 | ||||
| Market Capitalization | 98.09 M | ||||
| Total Asset | 66.27 M | ||||
| Retained Earnings | (415.7 M) | ||||
| Working Capital | 47.9 M | ||||
| Current Asset | 22.73 M | ||||
| Current Liabilities | 1.49 M | ||||
| Net Asset | 66.27 M |
About MediciNova Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze MediciNova's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MediciNova using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MediciNova based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for MediciNova Stock Analysis
When running MediciNova's price analysis, check to measure MediciNova's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MediciNova is operating at the current time. Most of MediciNova's value examination focuses on studying past and present price action to predict the probability of MediciNova's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MediciNova's price. Additionally, you may evaluate how the addition of MediciNova to your portfolios can decrease your overall portfolio volatility.